Preface content

Novel Tools, Resources and Technologies

Research Gaps


  • Better field evaluation methods
  • Lack of tools for veterinary medical research, in particular to measure proteins
  • Predictive molecular tools to monitor how vaccine will perform
  • Immunological reagents to define/characterize correlates of protection/vaccine induced immune responses
  • Unavailability of systems/tools for the induction of class I MHC restricted T cell responses in large mammals.
  • Comprehensive sets of cell surface markers and cytokine reagents for the veterinary species.
  • Tools and methods to evaluate immunogenicity/ protective efficacy of vaccines
  • Tools and reagents to probe immune responses in a variety of veterinary species


  • Adjuvants and adjuvant technologies that work in veterinary species and are species- specific
  • Development of novel delivery systems and adjuvants.
  • commercialisable adjuvants
  • Suitable and safe adjuvants for inactivated or recombinant protein vaccines
  • How adjuvants compare against each other and between species
  • Development of adjuvants to stimulate mucosal immunity with inactivated antigens in mammalian, poultry and aquatic species
  • Appropriate adjuvants that would balance Th1 and Th2 response
  • Strategic use of adjuvants and other immuno-enhancers and immuno-modulators
  • Understanding the mechanism of adjuvant action, improving targeting and reducing side effects


  • Vaccine vectors
  • Better delivery platforms for vaccines (e.g. vectors)
  • New generation viral vector based vaccine that induces innate and cellular immunity in addition to humoral immunity


  • Development of in vitro models that more closely mimic the host-pathogen interaction in protective as well as in pathogenic responses during the process of vaccination and infection.
  • In vitro models will facilitate mathematical model development which in turn will feed back potential in vivo hypothesis driven research avenues.
  • Development of novel fish cell lines
  • The availability of high quality in vitro and in vivo models for the efficacy and safety evaluation of veterinary vaccines for endemic and exotic veterinary diseases

Embracing New Technologies

  • Nanotechnology being applied to livestock vaccines
  • Embracing new vaccine technologies (e.g DNA vaccines)
  • Novel synthetic biology approaches to vaccine development
  • Platform technology for virus candidate vaccines
  • Systems biology and reverse vaccinology approaches.

Call to action content


Trim content

Copyright: The Pirbright Institute 2014-2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.